31 Previous studies suggest that NHB women may have higher ODX RS on average compared to their white counterparts,32,33 which may reflect use patterns or less favorable tumor biology for ER-positive disease. Oncotype DX was developed in a primarily homogenous NHW population, although with ...
Oncotype DX testing is supported by both the American Society of Clinical Oncology and the National Comprehensive Cancer Network for guiding management in breast cancer patients with node- negative, ER-positive disease,42,43 and is clearly recognized as a valuable test in the literature.30,47–49...
Genomic Health Expands Offering to Prostate Cancer Patients with Launch of Oncotype DX(R) AR-V7 Nucleus Detect(TM) Test to Predict Treatment Response in Metastatic Disease New Liquid Biopsy Test Helps Physicians Select Most Effective Treatment, Prolonging Lives of Men with Metastatic Castration-resistan...
英文标题:YL202/BNT326, a HER3-targeted ADC, in patients with locally advanced or metastatic non-small cell lung cancer and breast cancer: Preliminary results from a first-in-human phase I trial. 中文标题:HER3 ADC药物YL202/BNT326用于局部晚期...
[20] Mimoto R, Yogosawa S, Saijo H, et al. Clinical implications of drug-screening assay for recurrent metastatic hormone receptor-positive, human epidermal receptor 2-negative breast cancer using conditionally reprogrammed ce...